Authors

Latest:

New OncLive Podcast Series Launches With Focus on Gynecologic Oncology

OncLive has launched a new podcast series, From Discovery to Delivery: Charting Progress in Gynecologic Oncology, hosted by Ursula A. Matulonis, MD.

Paolo Tarantino, MD

Paolo Tarantino, MD is an Advanced Research Fellow in the Breast Oncology Program at Dana-Farber Cancer Institute and Harvard Medical School.

Latest:

Clinical Significance of ADC in Breast Cancer: Updates Presented at ESMO 2025

Experts analyze groundbreaking antibody drug conjugate findings from ESMO 2025, highlighting their impact on breast cancer treatment strategies and patient care.

Russell J. Ledet, PhD

Latest:

A Prayer for a More Equitable Future

Russell J. Ledet, PhD, discusses being a Black man in the field of oncology.

Adam L. Johnson, MD

Latest:

The Mullin Sisters

A breast surgical oncology fellow tells the story of how 3 women in his family helped shape his career and provide a purpose for his passion.

Jaime Schneider, MD, PhD

Latest:

Dr Schneider on Treatment Considerations After Osimertinib in EGFR+ NSCLC

Jaime Schneider, MD, PhD, discusses considerations for patients with EGFR-mutant non–small cell lung cancer that progresses on osimertinib.

Jayesh Desai, MBBS, FRACP

Latest:

Phase IB Study of GDC-6036 in Combination with Cetuximab in Patients With Colorectal Cancer (CRC) With KRAS G12C Mutation

Jayesh Desai, MBBS, FRACP, shares data from a phase IB study investigating KRAS G12C inhibitor GDC-6036, or divarasib, in combination with cetuximab for the treatment of patients with colorectal cancer.

Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD

Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, is an associate professor and the lymphoma stream lead at St Vincent’s Hospital

Latest:

Dr Ku on the Rationale for Evaluating JNJ-90014496 in Relapsed/Refractory LBCL

Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, details the rationale for assessing a dual bispecific CAR T-cell therapy in relapsed/refractory LBCL.

Alexander Spira, MD, PhD, FACP, Director, Virginia Cancer Specialists Research Institute

Latest:

Raising the Bar in the First-Line Treatment of EGFR+* mNSCLC Advanced Lung Cancer

Bharat Sanders

Latest:

Taking Back Our Empathy: Reflections on a New Model of Medical Education

Bharat Sanders sheds light on how patient-centered medical education put him behind the eyes of the patient and fundamentally changed the way he practices medicine.

Monalisa Ghosh, MD

Latest:

Dr. Ghosh on the Role of Off-the-Shelf CAR T-Cell Therapy in Myeloma

Monalisa Ghosh, MD, discusses the role of off-the-shelf CAR T-cell therapy in patients with multiple myeloma.

Kanwal Raghav, MD, MBBS, The University of Texas MD Anderson Cancer Center

Latest:

Dr Raghav on a Phase 2 Study of ABBV-400 Plus Fluorouracil, Folinic Acid, and Bevacizumab in Pretreated Metastatic CRC

Kanwal P.S. Raghav, MD, MBBS, discusses a phase 2 study of ABBV-400 plus 5-FU, folinic acid, and bevacizumab in pretreated patients with metastatic CRC.

Amin Sobh, PhD

Amin Sobh, PhD, is a research assistant professor in the Division of Hematology/Oncology at the University of Florida College of Medicine

Latest:

Dr Sobh on the Therapeutic Potential of Selectively Targeting NSD2 in Multiple Myeloma

Armin Sobh, PhD, discusses the therapeutic potential of selectively targeting NSD2 in the treatment of multiple myeloma.

Christine Bestvina, MD, University of Chicago

Latest:

Charting the Future: Key Therapies for Managing EGFR-Mutant NSCLC

This episode focuses on exploring additional therapeutic options for managing previously treated advanced or metastatic EGFR-mutated NSCLC, highlighting strategies to optimize patient survival across various stages of disease progression.

Amanda Bloomer, PhD

Latest:

Dr Bloomer on the Rationale for the ColoCare Study in Newly Diagnosed CRC

Amanda Bloomer, PhD, discusses the rationale for launching the ColoCare study, an investigation into the health-related quality of life outcomes of younger vs older adult patients with newly diagnosed colorectal cancer.

Amandeep Godara, MBBS

Latest:

Dr Godara on the Selection of CAR T-Cell Therapies vs Bispecific Antibodies in R/R Multiple Myeloma

Amandeep Godara, MBBS, discusses important patient factors to consider when deciding between a CAR T-cell therapy vs bispecific antibody in relapsed/refractory multiple myeloma, and the importance of mitigating treatment-related toxicities associated with the administration of bispecific antibodies in this disease setting.

Ariel Perez Perez, MD

Latest:

Dr. Perez Perez on Results From a Retrospective Study of Polatuzumab Regimens in R/R LBCL

Ariel Perez Perez, MD, discusses key results and clinical implications from a retrospective study of polatuzumab-vedotin plus rituximab with or without bendamustine in relapsed/refractory large B-cell lymphomas.

Ann W. Silk, MD, MS

Latest:

Extending the Frontiers of Checkpoint Inhibition in Merkel Cell Carcinoma

In the treatment of unresectable or metastatic Merkel cell carcinoma, immune checkpoint inhibitors have activity and tolerability.

Matthew H. G. Katz, MD, CMQ, FACS, FASCO

Latest:

Dr. Katz on Neoadjuvant mFOLFIRINOX in Pancreatic Cancer

Matthew H. G. Katz, MD, CMQ, FACS, FASCO, discusses the efficacy of mFOLFIRINOX, a chemotherapy regimen consisting of oxaliplatin, irinotecan, leucovorin, and fluorouracil, prior to pancreatectomy in patients with borderline resectable pancreatic cancer.

Ashraf Badros, MBCHB

Latest:

Dr Badros on the Design of the AURIGA Study of Daratumumab/Lenalidomide in Newly Diagnosed Myeloma

Ashraf Z. Badros, MBCHB, discusses the design of the AURIGA trial of daratumumab plus lenalidomide in newly diagnosed myeloma following transplant.

Ryan Cassaday, MD

Latest:

Blinatumomab-Based Regimens Enhance and Refine the B-ALL Treatment Paradigm: With Ryan Cassaday, MD

Ryan Cassaday, MD, discussed insights from trials investigating blinatumomab in patients with B-ALL that were reported at the 2024 ASH Annual Meeting.